FDA pipeline preview, March 2008

NDA Resubmitted for Dry Eye Treatment Reproxalap

UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.

Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.

Blue Shield of California to Offer Humira Biosimilar Idacio

Otulfi is the fourth Stelara biosimilar to be approved by the FDA.

FDA Approves Dupixent for Patients with COPD

Blue Shield of California is purchasing Idacio for a net price of $525 per monthly dose, and most plan members will pay $0 out of pocket.

FDA Approves the Oral Medication KarXT for Schizophrenia

This is the sixth indication for Dupixent and the only biologic approved in the United States to treat COPD.

UnitedHealthcare Adds Deductibles to Medicare Part D for 2025

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

Related Content

NDA Resubmitted for Dry Eye Treatment Reproxalap

UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.

Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.

Blue Shield of California to Offer Humira Biosimilar Idacio

Otulfi is the fourth Stelara biosimilar to be approved by the FDA.

FDA Approves Dupixent for Patients with COPD

Blue Shield of California is purchasing Idacio for a net price of $525 per monthly dose, and most plan members will pay $0 out of pocket.

FDA Approves the Oral Medication KarXT for Schizophrenia

This is the sixth indication for Dupixent and the only biologic approved in the United States to treat COPD.